Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Jun;1(2):123-6.
doi: 10.1007/s12245-008-0020-8.

Tetanus antibody protection among HIV-infected US-born patients and immigrants

K Alagappan  1 , J McGowan, D DeClaro, D Ng, R A Silverman
Affiliations

Tetanus antibody protection among HIV-infected US-born patients and immigrants

K Alagappan et al. Int J Emerg Med. 2008 Jun.

Abstract

Introduction: Public health initiatives to immunize children and adults have effectively reduced the number of tetanus cases in the USA. However, in the Third National Health and Nutrition Examination Survey (NHANES III), immigrants from Mexico had a 67% nonprotective anti-tetanus antibody (ATA) level. Less work has been conducted among other vulnerable populations such as human immunodeficiency virus (HIV)-infected patients. The objective of this study was to measure ATA levels among the HIV immigrant population compared with US-born HIV-infected patients.

Methods: A convenience sample of 158 HIV-infected individuals was recruited to determine the levels of ATA. A nonprotective level of ATA was defined as below 0.15 IU/ml.

Results: Among the HIV-infected patients, 72% (114/158) were born in the USA. A total of 17% (27/158) lacked protective levels of ATA. A total of 6.1% (7/114) of those born in the USA lacked protection, compared to 45% (20/44) born outside the USA (p < 0.0001).

Conclusion: The results illustrate that the country of birth is an important predictor of ATA protection, even among HIV-infected patients.

PubMed Disclaimer

References

    1. Centers for Disease Control and Prevention (2007) Epidemiology and prevention of vaccine-preventable diseases, 10th edn. Atkinson W, Hamborsky J, McIntyre L, Wolfe S (eds). Public Health Foundation, Washington, DC
    1. Pascual FB, McGinley EL, Zanardi LR, Cortese MM, Murphy TV. Tetanus surveillance — United States, 1998—2000. MMWR Surveill Summ. 2003;52(3):1–8. - PubMed
    1. Centers for Disease Control and Prevention Recommended childhood immunization schedule—United States, 2003. MMWR Morb Mortal Wkly Rep. 2003;52:Q1–Q4. - PubMed
    1. Kretsinger K, Broder KR, Cortese MM, Joyce MP, Ortega-Sanchez I, Lee GM, Tiwari T, Cohn AC, Slade BA, Iskander JK, Mijalski CM, Brown KH, Murphy TV, Centers for Disease Control and Prevention. Advisory Committee on Immunization Practices. Healthcare Infection Control Practices Advisory Committee Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine recommendations of the Advisory Committee on Immunization Practices (ACIP) and recommendation of ACIP, supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for use of Tdap among health-care personnel. MMWR Recomm Rep. 2006;55(RR-17):1–37. - PubMed
    1. Gergen PJ, McQuillan GM, Kiely M, et al. A population-based serologic survey of immunity to tetanus in the United States. N Engl J Med. 1995;332:761–766. doi: 10.1056/NEJM199503233321201. - DOI - PubMed

LinkOut - more resources